The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Tumor Sample - Analyzed for TCR Repertoire and Global Transcription Profiling
研究概览
简要总结
The proposed study aims to investigate how the administration of a drug known to reduce inflammation in humans, Celecoxib, will effect the peri-operative inflammatory response of a patient undergoing primary tumor resection surgery for colon cancer. The proposed project is an exploratory study, and will use data from blood samples and tumor samples to attempt to elucidate the immune and inflammatory response in colon cancer patients undergoing primary resection of their tumors.
详细描述
This study is the first to assess the perioperative time course of systemic inflammation and immunity in colon cancer patients and evaluate the effect of anti-inflammatory treatment with celecoxib on this response. In addition, evaluation of the effect of short-term preoperative administration of celecoxib on tumor immunogenicity will help us to understand how tumor-enhancing inflammation and anti-tumor immunity can be differentially affected by COX-2 inhibitors. The knowledge gained as a result of this research will help us to set up the infrastructure for a method to monitor the immunoinflammatory status of colon cancer patients with a longer term goal of designing interventions to suppress tumor-enhancing inflammation and vitalize anti-tumor immunity in the perioperative period. The long-term objective is to use these novel tools in order to improve cancer-specific survival in patients with colon cancer after primary tumor resection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage I-III), who are
- •between 18 and 75 years old,
- •have a body mass index (BMI) between 18 and 35 kg/m^2,
- •and are eligible for laparoscopically-assisted colectomy for primary tumor resection.
- •Patients must have the ability to understand and the willingness to sign a written informed consent document.
排除标准
- •A history of allergic-type reactions to celecoxib or sulphonamides,
- •a history of asthma, skin reactions or other allergic reactions to aspirin or other NSAIDs,
- •a history of thromboembolic event (cerebrovascular accident, transient ischemic attack,
- •unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),
- •renal insufficiency (defined by a serum creatinine level > 1.5 mg/dL or blood urea nitrogen level > 22 mg/dL),
- •active gastrointestinal bleeding in the 60 days before surgery,
- •alcohol or drug abuse, and
- •previous chemotherapy or abdominal/pelvic radiation therapy.
- •After randomization, other exclusion criteria will include a surgical procedure longer than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a new postoperative myocardial infarction, abnormal postoperative mental status or any new neurologic deficit, significant postoperative bleeding (with a hemoglobin level < 7.5 g/dL), requiring blood transfusion, or a urine output of less than 30 mL/h.
研究组 & 干预措施
Celecoxib
Celecoxib, 200 mg tab
干预措施: Celecoxib (Drug)
Placebo
placebo, tab
干预措施: placebo (Other)
结局指标
主要结局
Tumor Sample - Analyzed for TCR Repertoire and Global Transcription Profiling
时间窗: 2 years
Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.
时间窗: 30 days
次要结局
- Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op.(30 days)
研究者
Anthony Doufas
Associate Professor
Stanford University